Pyrotinib
Microsatellite Stable
Zhejiang Cancer HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
17 Active assets in the Microsatellite Stable cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan M.D. Anderson Cancer Center | Phase 2 | BB |
Eloxatin M.D. Anderson Cancer Center | Phase 2 | BB |
Epirubicin NextCure, Inc. | Phase 2 | B |
Pembrolizumab NextCure, Inc. | Phase 2 | B |
Cyclophosphamide NextCure, Inc. | Phase 2 | B |
View all 18 →
Same molecule, other indications
Pyrotinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →